Telix Pharmaceuticals Limited (TLX,TLX.AX) reported that its operating profit for the first-half of 2025 dropped to US$10.4 million from US$27.7 million in the prior year. Loss before tax was US$4.8 million compared to profit of US$22.9 million in the prior year. The latest period results included US$12.4 million in non-cash finance costs associated with convertible bonds issued in July 2024 and increased amortization cot of US$9.5 million following RLS acquisition.
Revenue for the period was US$390.4 million, up 63% from last year.
Telix confirmed fiscal year 2025 revenue guidance of US$770 million to US$800 million.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.